EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Ana Gómez Rueda, Álvaro Taus, Rosa Álvarez Álvarez, Reyes Bernabé-Caro, Luis Chara, Marta López-Brea, Laia Vilà, Maria Ángeles Sala González, Anabel Del Barrio Díaz Aldagalán, Beatriz Esteban Herrera, Rafael López Castro, Ruth Álvarez Cabellos und 28 weitere

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03404-9 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Ana Gómez Rueda und 39 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Carretera Colmenar ViejoKM 9100, 28034, Madrid, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Antibodies, Monoclonal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The S-REAL study aimed to assess the effectiveness of durvalumab as consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world cohort of patients with locally advanced, unresectable stage III non-small cell lung cancer (LA-NSCLC) included in a Spanish early access program (EAP). METHODS: In this multicentre, observational, retrospective study we analysed data from patients treated in 39 Spanish hospitals, who started intravenous durvalumab (10 mg/kg every 2 weeks) between September 2017 and December 2018. The primary endpoint was progression-free survival (PFS). Secondary endpoints included patient characterization and adverse events of special interest (AESI). RESULTS: A total of 244 patients were followed up for a median of 21.9 months [range 1.2-34.7]. Median duration of durvalumab was 45.5 weeks (11.4 months) [0-145]. Median PFS was 16.7 months (95% CI 12.2-25). No remarkable differences in PFS were observed between patients with programmed cell death-ligand 1 (PD-L1) expression ≥ 1% or < 1% (16.7 versus 15.6 months, respectively). However, PFS was higher in patients who had received prior concurrent CRT (cCRT) versus sequential CRT (sCRT) (20.6 versus 9.4 months). AESIs leading to durvalumab discontinuation were registered in 11.1% of patients. CONCLUSIONS: These results are in line with prior published evidence and confirm the benefits of durvalumab in the treatment of LA-NSCLC patients in a real-world setting. We also observed a lower incidence of important treatment-associated toxicities, such as pneumonitis, compared with the pivotal phase III PACIFIC clinical study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyAntibodies, MonoclonalHumansMaleFemaleRetrospective StudiesAgedMiddle AgedSpainAdultAged, 80 and overAntineoplastic Agents, ImmunologicalNeoplasm StagingProgression-Free SurvivalConsolidation ChemotherapyB7-H1 Antigen

Stichwörter der Autor:innen

ChemoradiotherapyDurvalumabNSCLCPD-L1PFSReal-world

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Carretera Colmenar ViejoKM 9100, 28034, Madrid, Spain.
  • Medical Oncology Department, Hospital del Mar, Barcelona, Spain.
  • Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Medical Oncology Department, Hospital Virgen del Rocío, Seville, Spain.
  • Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
  • Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Zitieren

APA

Gómez Rueda, A., Taus, Á., Álvarez Álvarez, R., Bernabé-Caro, R., Chara, L., López-Brea, M., Vilà, L., Sala González, M. Á., Del Barrio Díaz Aldagalán, A., Esteban Herrera, B., López Castro, R., Álvarez Cabellos, R., Doménech, M., Falagan, S., Moreno Vega, A., Aguado, C., Barba, A., Delgado Ureña, M. T., Isla, D., …, & Spanish Lung Cancer Group (2024). The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03404-9

Vancouver

Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, et al. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03404-9

BibTeX
@article{GmezRueda2024,
  author = {Gómez Rueda, Ana and Taus, Álvaro and Álvarez Álvarez, Rosa and Bernabé-Caro, Reyes and Chara, Luis and López-Brea, Marta and Vilà, Laia and Sala González, Maria Ángeles and Del Barrio Díaz Aldagalán, Anabel and Esteban Herrera, Beatriz and López Castro, Rafael and Álvarez Cabellos, Ruth and Doménech, Marta and Falagan, Sandra and Moreno Vega, Alberto and Aguado, Carlos and Barba, Andrés and Delgado Ureña, Maria Teresa and Isla, Dolores and Bellido Hernández, Lorena and Fírvida Pérez, José Luis and Juan-Vidal, Óscar and Massutí, Bartomeu and Mielgo-Rubio, Xabier and Ortega, Ana Laura and Catot, Silvia and Dómine, Manuel and Escoín-Pérez, Corina and García Navalón, Francisco and Gil-Bazo, Ignacio and Muñoz, Silvia and Rodríguez-Abreu, Delvys and Villatoro Roldán, Rosa María and Alonso-Jáudenes Curbera, Guillermo and León-Mateos, Luis and Padilla, Airam and Paredes Lario, Alfredo and Sánchez-Torres, José Miguel and Garrido, Pilar and Spanish Lung Cancer Group, Spanish Lung Cancer Group},
  title = {The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03404-9}
}
Kostenlos starten →